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Abstract 
Background: Emerging evidence suggests that specific (poly)phenols may constitute new preventative strategies to 
counteract cell oxidative stress and myocardial tissue inflammation, which have a key role in the patho-physiology of 
diabetic cardiomyopathy. In a rat model of early diabetes, we evaluated whether in vivo administration of urolithin A 
(UA) or urolithin B (UB), the main gut microbiota phenolic metabolites of ellagitannin-rich foods, can reduce diabetes-
induced microenvironmental changes in myocardial tissue, preventing cardiac functional impairment.
Methods: Adult Wistar rats with streptozotocin-induced type-1 diabetes (n = 29) were studied in comparison with 
10 control animals. Diabetic rats were either untreated (n =  9) or subjected to daily i.p. injection of UA (n = 10) or 
UB (n = 10). After 3 weeks of hyperglycaemia, hemodynamics, cardiomyocyte contractile properties and calcium 
transients were measured to assess cardiac performance. The myocardial expression of the pro-inflammatory cytokine 
fractalkine and proteins involved in calcium dynamics (sarcoplasmic reticulum calcium ATPase, phospholamban and 
phosphorylated phospholamban) were evaluated by immunoblotting. Plasma, urine and tissue distribution of UA, UB 
and their phase II metabolites were determined.
Results: In vivo urolithin treatment reduced by approximately 30% the myocardial expression of the pro-inflamma-
tory cytokine fractalkine, preventing the early inflammatory response of cardiac cells to hyperglycaemia. The improve-
ment in myocardial microenvironment had a functional counterpart, as documented by the increase in the maximal 
rate of ventricular pressure rise compared to diabetic group (+18% and +31% in UA and UB treated rats, respectively), 
and the parallel reduction in the isovolumic contraction time (−12%). In line with hemodynamic data, both urolithins 
induced a recovery of cardiomyocyte contractility and calcium dynamics, leading to a higher re-lengthening rate 
(+21%, on average), lower re-lengthening times (−56%), and a more efficient cytosolic calcium clearing (−32% in 
tau values). UB treatment also increased the velocity of shortening (+27%). Urolithin metabolites accumulated in the 
myocardium, with a higher concentration of UB and UB-sulphate, potentially explaining the slightly higher efficacy of 
UB administration.
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Background
Diabetic cardiomyopathy (DCM), defined as ventricu-
lar dysfunction in the absence of concurrent coronary 
artery disease and/or hypertension, constitutes one of the 
major complication of both type-1 and type-2 diabetes 
[1]. Since the early stages of diabetes, the altered tissue 
microenvironment associated with metabolic changes, 
including hyperglycaemia, cell oxidative stress and up-
regulation of inflammatory cytokines, can directly affect 
multiple intracellular molecular pathways which impair 
cardiomyocyte contractility and promote structural dam-
age [1–4].
In the last decade, several studies have focused on 
novel therapeutic adjuvant strategies to counteract early 
hyperglycaemia-induced changes in myocardial micro-
environment and the associated morpho-functional 
alterations in the diabetic myocardial tissue [5–7]. In 
this context, specific attention has recently been devoted 
to different dietary (poly)phenols which have been 
shown to be potentially bioactive due to their antioxi-
dant and anti-inflammatory properties [2, 8], leading to 
cardioprotection, in both diabetic and ischemic hearts. 
Among these compounds, ellagitannins (ETs), a sub-
class of hydrolysable tannins present mainly in raspber-
ries, strawberries, pomegranate, walnuts, and oak-aged 
red wines [9], are known to exert different bioactivities 
[10, 11]. ETs are hydrolysed in the gut to release ellagic 
acid, which is further processed by the gut microbiota 
into a series of metabolites named urolithins, each char-
acterised by a specific hydroxylation pattern. Urolithin 
A (UA, 3,8-dihydroxy-urolithin) and urolithin B (UB, 
3-hydroxy-urolithin) are the main urolithins detected in 
human biological fluids and tissues after ET consump-
tion by humans, while other urolithins such as urolithin 
C (UC, 3,8,9-trihydroxy-urolithin) and urolithin D (UD, 
3,4,8,9-tetrahydroxy-urolithin) may be found at lower 
concentrations [9, 10, 12]. Urolithins can be further 
metabolised, mainly by enterocytes and hepatocytes, 
by phase II enzymes yielding glucuronide, sulphate, and 
methyl derivatives which appear in the circulation at high 
nM to low µM concentrations. It has been shown that 
UB, UB-glucuronide and UD, at a concentration coher-
ent with a dietary exposure to ET-rich foods, are able 
to modulate the pro-inflammatory mediators secreted 
by cultured neonatal cardiac cells, cardiomyocytes and 
fibroblasts, after 3-weeks exposure to high glucose con-
centrations [13]. Specifically, UB and UB-glucuronide 
prevented inflammatory responses in cardiomyocytes, 
while UD reduced the over-expression of the pro-
inflammatory cytokine fractalkine by cardiac fibroblasts. 
However, no in vivo data are currently available demon-
strating the functional counterpart of the positive impact 
of urolithins on diabetes-induced microenvironmental 
changes.
This paper specifically addresses this issue in order to 
investigate the effects of urolithin administration on the 
recovery of cardiac function, as measured at organ and 
cellular levels, and on the inflammatory state of myo-
cardial tissue in a rat model of early diabetes induced by 
streptozotocin. The presence of urolithin metabolites in 
the cardiac tissue and other biological tissues/fluids was 
also assessed to better understand the effect of these phe-
nolic metabolites on DCM prevention.
Methods
The investigation was approved by the Veterinary Animal 
Care and Use Committee of the University of Parma-Italy 
(Prot. No. 59/12) and conforms to the National Ethical 
Guidelines of the Italian Ministry of Health and the Guide 
for the Care and Use of Laboratory Animals (National 
Institute of Health, Bethesda, MD, USA, revised 1996). 
All experiments were carried out in accordance with the 
approved guidelines.
Animals and experimental protocol
The study population consisted of 39 male Wistar 
rats (Rattus norvegicus) aged 12–14  weeks, weighing 
376.4 ± 4.9 g (standard error of the mean, SEM). Animals 
were kept in unisexual groups of four individuals from 
weaning, 4 weeks after birth, until the onset of the exper-
iments, in a temperature-controlled room at 22–24  °C, 
illuminated from 0700 to 1900  h. The bedding of the 
cages consisted of wood shavings, and food and water 
were freely available. Type-1 diabetes was induced in 29 
animals (group D) by a single intra-peritoneal (i.p.) injec-
tion of streptozotocin (STZ, 60  mg/kg, Sigma-Aldrich, 
Milan, Italy) while the remaining 10 control rats (CTRL 
group) were injected only with the vehicle (0.9% NaCl). 
Glucose blood levels and body weights were measured 
in 4-h-fasting animals, before STZ or vehicle injection, 
then after 2  days, and weekly until sacrifice 3  weeks 
after the induction of hyperglycaemia. D animals were 
either untreated (D3 group, n  =   9) or subjected to daily 
i.p. injection of UA (Toronto Research Chemicals Inc., 
Conclusions: In vivo urolithin administration may be able to prevent the initial inflammatory response of myocardial 
tissue to hyperglycaemia and the negative impact of the altered diabetic milieu on cardiac performance.
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Toronto, ON, Canada) (D3-UA, n = 10) or UB (Toronto 
Research Chemicals) (D3-UB, n  =  10), at a dose of 
2.5 mg/kg/day.
The treatment started immediately after the docu-
mented increase in blood glucose levels (2 days after STZ 
injection; blood glucose cut-off: 250  mg/dl). To prepare 
UA and UB stock solutions, the compounds were dis-
solved in dimethyl sulfoxide (DMSO, Sigma-Aldrich) at 
50  mg/ml and stored in darkness at 4  °C. For each ani-
mal, immediately prior to i.p. injection, an appropriate 
aliquot was taken from the stock solution and diluted in 
PBS to reach the desired concentration in a final volume 
of 250 µl.
Hemodynamic measurements were performed under 
anaesthesia in all CTRL rats and in all D animals after 
3 weeks of hyperglycaemia (D3, D3-UA and D3-UB). This 
early stage of diabetes is characterised by the occurrence 
of the first signs of cardiomyocyte contractile dysfunc-
tion associated with changes in myocardial tissue micro-
environment, in the absence of marked cardiac structural 
damage, collagen accumulation or inflammatory cell 
infiltrate [2].
Immediately after hemodynamic measurements, in 
subgroups of each experimental group, the heart was 
excised and cardiac cells were enzymatically isolated 
to measure cardiomyocyte mechanical properties and 
calcium transients. From the remaining rats, blood 
and urine samples were collected by inferior vena cava 
withdrawal and direct puncture of the exposed bladder, 
respectively. Urine samples were stored at −20 °C, while 
blood was centrifuged (2680g for 15 min at 4 °C) to obtain 
plasma. Then, after pancreas and liver removal, the heart 
was rapidly excised and perfused with a 0.9% NaCl solu-
tion to drain the residual blood. Finally, the tissues (left 
and right ventricles, liver, and pancreas) were wiped with 
filter paper, weighted, mechanically fragmented in liquid 
nitrogen and stored at −80  °C. Plasma, urine and tis-
sues were used for determining the distribution of UA, 
UB and their metabolites. Heart tissue was also used for 
molecular analyses.
Plasma, urine and tissue processing prior to UHPLC‑MS/MS 
analysis
Plasma samples were defrosted, vortexed, and extracted 
as previously reported [14]. Briefly, 400  μl plasma ali-
quots were mixed with 1 ml of acidified acetonitrile (2% 
formic acid, Sigma-Aldrich). Samples were vortexed, 
ultrasonicated for 10 min, and centrifuged at 16,000g for 
10  min. The supernatant was reduced to dryness using 
a Speedvac concentrator (Thermo Fisher Scientific Inc., 
San José, CA, USA), the pellet was then suspended in 
100  μl of 50% (v:v) methanol (Sigma-Aldrich) acidified 
with 0.1% (v:v) formic acid, and centrifuged at 16,000g 
for 5 min prior to analysis by ultra-high performance liq-
uid chromatography-mass spectrometry (UHPLC-MS/
MS).
Urine was defrosted, centrifuged at 16,000g for 5 min, 
and diluted 1:4 with water containing 0.1% formic acid. 
Powdered tissues were extracted by using a protocol 
similar to that used for plasma samples but following 
repeated extractions. Briefly, from each tissue sample 
(~1 g), proteins were precipitated with 1500 μl of 2% for-
mic acid in acetonitrile (the solvent volume for extrac-
tion was modified proportionately to the total weight 
of the samples). The samples were then vortexed vigor-
ously for 5  min, placed in a sonicator bath for 10  min, 
and centrifuged (16,000g for 5 min). A second extraction 
was performed for each sample with 3  ml of acidified 
acetonitrile as described above. The two supernatants 
were pooled and dried under vacuum. Finally, the pellet 
was suspended in 100  μl of methanol:water:formic acid 
(50:50:0.1, v/v/v) and centrifuged at 16,000g for 5  min 
before analysis.
UHPLC‑MS/MS analysis
Plasma, urine, heart ventricles, liver, and pancreas sam-
ples were analysed according to Mele et  al. [15] with 
minor modifications. Briefly, samples were run using an 
Accela UHPLC 1250 equipped with a linear ion trap-mass 
spectrometer (LTQ XL, Thermo Fisher Scientific) fitted 
with a heated-electrospray ionization probe (H-ESI-II). 
Separations were performed using a XSELECTED HSS 
T3 (50 × 2.1 mm), 2.5 μm particle size (Waters, Milford, 
MA, USA), with an injection volume of 5 μl, column oven 
temperature of 40 °C and elution flow rate of 0.3 ml/min. 
The initial gradient was 80 of 0.1% aqueous formic acid 
and 20% acetonitrile (in 0.1% formic acid), reaching 80% 
acetonitrile at 6  min. The MS conditions included: cap-
illary temperature of 275 °C and source heater tempera-
ture of 250 °C, sheath gas flow of 60 units, auxiliary gas of 
7 units, source voltage of 3.5 kV, and capillary voltage and 
tube lens of −39 and −88 V, respectively. Analyses were 
carried out using specific  MS2 full scans corresponding 
to the putative phase II metabolites of UA and UB (glucu-
ronide, sulphate, methyl, or a combination thereof ), with 
collision induced dissociation (CID) equal to 35 (arbi-
trary units) (Table 1). After this first step, further specific 
 MS3 analyses were carried out to unambiguously identify 
the compounds revealed in the first step. Pure helium gas 
was used for CID. Data processing was performed using 
Xcalibur software from Thermo Scientific. Quantification 
was performed with calibration curves of pure standards 
in the case of UA, UB, and UB-glucuronide (provided by 
Prof. O. Dangles, INRA, Avignon, France). UA-sulphate 
was expressed as UA equivalents, while UB-sulphate as 
UB equivalents.
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Hemodynamic study
Invasive hemodynamic data were recorded in 39 rats (10 
CTRL, 9 D3, 10 D3-UA, and 10 D3-UB). After anaes-
thesia with ketamine chloride (Imalgene, Merial, Milan, 
Italy; 40  mg/kg i.p.) plus medetomidine hydrochlo-
ride (Domitor, Pfizer Italia S.r.l., Latina, Italy; 0.15  mg/
kg i.p.), the right carotid artery was cannulated with a 
microtip pressure transducer catheter (Millar SPC-320, 
Millar Instruments, Houston, TX, USA) connected to a 
recording system (Power Laboratory ML 845/4 channels, 
2Biological Instruments, Besozzo, Italy) and systolic and 
diastolic blood pressures were determined. The catheter 
was then advanced into the left ventricle to measure the 
following parameters: left ventricular (LV) systolic pres-
sure (LVSP), LV end-diastolic pressure (LVEDP), the 
maximum rate of ventricular pressure rise (+dP/dtmax) 
and reduction (−dP/dtmax), taken as indexes of myocar-
dial mechanical efficiency, isovolumic contraction time 
(IVCT: duration of isovolumic contraction), and total 
cycle duration (Tcycle) (software package CHART B4.2).
Isolation of adult left ventricular cardiomyocytes
From the heart of 6 CTRL, 6 D3, 5 D3-UA, and 4 D3-UB 
rats, individual LV myocytes were enzymatically isolated 
by collagenase perfusion. Briefly, the heart was rapidly 
excised through median sternotomy and mounted on a 
Langendorff isolated heart apparatus. The heart was then 
perfused at 37  °C by cannulating the aorta with the fol-
lowing sequence of solutions gassed with 100% oxygen: 
(1) calcium-free solution for 5 min to remove the blood, 
(2) low-calcium solution (0.1 mM) plus 1 mg/ml type 2 
collagenase (Worthington Biochemical Corporation, 
Lakewood, NJ, USA) and 0.1  mg/ml type XIV protease 
(Sigma-Aldrich) for about 20  min, and (3) an enzyme-
free, low-calcium solution for 5 min. Calcium-free solu-
tion contained the following (in mM, all chemicals from 
Sigma-Aldrich): 126 NaCl, 22 dextrose, 5.0  MgCl2, 4.4 
KCl, 20 taurine, 5 creatine, 5 Na pyruvate, 1  NaH2PO4, 
and 24 HEPES (pH  =  7.4, adjusted with NaOH). The left 
ventricle was minced and shaken for 10  min. The cells 
were filtered through a nylon mesh and re-suspended in 
low-calcium solutions for 30  min (0.1 and 0.5  mM, for 
15  min each). Then, cells were used for measuring sar-
comere shortening and calcium transients.
Cardiomyocyte contractility and  Ca2+ transients
Mechanical properties of freshly isolated ventricular 
myocytes were assessed by using the IonOptix fluores-
cence and contractility systems (IonOptix, Milton, MA, 
USA). LV myocytes were placed in a chamber mounted 
on the stage of an inverted microscope (Nikon-Eclipse 
TE2000-U, Nikon Instruments, Florence, Italy) and 
superfused (1  ml/min at 37  °C) with a Tyrode solution 
containing (in mM; all chemicals from Sigma-Aldrich): 
140 NaCl, 5.4 KCl, 1  MgCl2, 5 HEPES, 5.5 glucose, and 
1  CaCl2 (pH 7.4, adjusted with NaOH). Only rod-shaped 
myocytes with clear edges and average sarcomere 
length  ≥1.7  µm were selected for the analysis, using a 
40× oil objective lens (NA: 1.3).
The cells were field stimulated at a frequency of 0.5 Hz 
by constant current pulses (2  ms in duration, and twice 
diastolic threshold in intensity; MyoPacer Field Stimulator, 
IonOptix). Load-free contraction of myocytes was meas-
ured with the IonOptix system, which captures sarcomere 
length dynamics via a Fast Fourier Transform algorithm. 
A total of 359 isolated ventricular myocytes were analysed 
(66 from CTRL hearts, 91 from D3, 100 from D3-UA, and 
102 from D3-UB) to compute the following parameters: 
mean diastolic sarcomere length, fraction of shortening 
(FS), maximal rates of shortening (−dL/dtmax) and re-
lengthening (+dL/dtmax), and time to 10, 50 and 90% of 
re-lengthening (time to basic length: TBL10%, TBL50%, 
and TBL90%). Steady-state contraction of myocytes was 
achieved before data recording by means of a 10 s condi-
tioning stimulation. Sampling rate was set at 1 kHz.
In a subset of cells of each group (33 from CTRL hearts, 
57 from D3, 63 from D3-UA, and 42 from D3-UB),  Ca2+ 
transients were measured simultaneously with cell 
motion.  Ca2+ transients were detected by epifluorescence 
after loading the myocytes with fluo-3-AM (10 µM; Invit-
rogen, Carlsbad, CA, USA) for 30 min. Excitation length 
was 480  nm, with emission collected at 535  nm. Fluo-3 
signals were expressed as normalized fluorescence (f/f0: 
fold increase). The time course of the fluorescence signal 
Table 1 Urolithins detected in rat fluids and tissues
PM plasma, U urine, H heart, PC pancreas, L liver, Rt retention time
a MS2 ions in italic were those subjected to  MS3 fragmentation for unambiguous identification
Urolithin Test compounds Rt (min) [M−H]− (m/z) MS2 ions (m/z) MS3 ions (m/z)a Occurrence
Urolithin B UB 3.62 211 167, 182 H, PC, L
UB-sulphate 2.83 291 211 167 PM, U, H, PC, L
UB-glucuronide 2.15 387 211, 175 167 PM
Urolithin A UA 2.51 227 183, 159, 199 PM, H, PC, L
UA-sulphate 1.79 307 227 198, 183 PM, H, PC, L
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decay was described by a single exponential equation, 
and the time constant (tau) was used as a measure of the 
rate of intracellular  Ca2+ clearing [16].
Electrophoretic and immunoblot assay
The hearts of 2 CTRL, 3 D3, 4 D3-UA, and 4 D3-UB were 
excised, and the left and right ventricles were weighed 
and immediately frozen at −80 °C, in order to determine 
the expression levels of the pro-inflammatory cytokine 
fractalkine (rabbit polyclonal ANTI-CX3CL1 antibody, 
1:1000, Abcam, Cambridge, UK), and the following pro-
teins involved in the intracellular calcium dynamics: the 
sarcoplasmic reticulum calcium ATPase 2 (SERCA2; rab-
bit polyclonal ANTI-SERCA2 ATPase antibody, 1:8000, 
Abcam), the regulatory protein phospholamban (PLB; 
mouse monoclonal ANTI-PHOSPHOLAMBAN anti-
body, 1:5000, Abcam) and the phosphorylated form of 
phospholamban (PLB-P; rabbit polyclonal ANTI- PHOS-
PHOLAMBAN (phospho S16) antibody, 1:1000, Abcam). 
The left and right ventricular tissue was mechanically frag-
mented in liquid nitrogen, and lysed with 300  µl of lysis 
buffer containing the following (all from Sigma-Aldrich): 
protease (1:100) and phosphatase (1:100) inhibitors, NaCl 
(150  mM), Tris–HCl (50  mM), EDTA (5  mM), Nonidet 
P-40 (1%), sodium fluoride solution (10  mM), sodium 
diphosphate dibasic (10  mM), SDS (0.1%) and sodium 
deoxycholate (0.5%). For each animal, equivalents of 50 µg 
of protein were separated on a 10% gradient SDS-PAGE 
gel for fractalkine and 4–20% gradient SDS-PAGE gel (Bio-
Rad, Hercules, CA, USA) for SERCA2, PLB, and PLB-P. 
Membranes were blocked with 5% milk in Tris-Buffered 
Saline Tween-20 (TBS-T, Sigma-Aldrich) and incubated 
overnight at 4  °C with the primary antibody. After wash-
ing the membranes, a second incubation was performed 
for 1 h at RT with peroxidase-conjugated affinity purified 
goat anti-rabbit (goat Anti-Rabbit IgG Horseradish Per-
oxidase Conjugate, 1:8000; Bio-Rad, Hercules, CA, USA) 
or anti-mouse (goat Anti-Mouse IgG Horseradish Peroxi-
dase Conjugate, 1:5000; Bio-Rad) secondary antibodies. 
Peroxidase activity was developed using the ECL Western 
blotting system (Amersham, Rahn AG, Zürich, Switzer-
land), according to the instructions of the manufacturer. 
Blots were scanned and the intensity of bands was quanti-
fied by means of the ImageJ software (NIH, Bethesda, MD, 
USA). All measurements were performed in technical trip-
licate. Actin (anti-actin rabbit polyclonal antibody, 1:5000, 
Sigma-Aldrich) was used as the loading control.
Statistical analysis
The IBM SPSS statistical package (International Business 
Machines Corporation, Armonk, NY, USA, version 23) 
was used. Normal distribution of variables was checked 
by means of the Kolmogorov–Smirnov test. Data are 
reported as mean values  ±  SEM, except the urolithin 
concentrations in fluids and tissues which were not nor-
mally distributed and were thus expressed as median and 
interquartile range (IQR). Comparisons among groups 
involved two-way ANOVA followed by post hoc individ-
ual comparisons with the Bonferroni or Games-Howell 
test, when appropriate (hemodynamics), 2-factor Nested 
ANOVA for repeated measurements (cell mechanics, 
and  Ca2+ transients), and non-parametric statistical test 
Kruskal–Wallis and U Mann–Whitney test (western blot 
data and urolithin concentrations). Differences were con-
sidered statistically significant at p < 0.05.
Results
Distribution and metabolism of urolithins
The administration of urolithin aglycones by i.p. injection 
guaranteed the presence of urolithin metabolites in cir-
culation, as assessed by evaluating the plasma concentra-
tion of UA and UB and their putative phase II conjugates 
(Tables 1, 2). In the case of UB treatment (D3-UB), only 
UB metabolites were found: UB-sulphate was the pre-
dominant metabolite and was found in all plasma sam-
ples from rats treated with UB, while UB-glucuronide 
was present in some but not all samples (4/9). The pro-
file of urolithin metabolites in circulation in the case of 
the animals treated with UA (D3-UA) was more complex: 
besides the aglycone form (UA) and UA-sulphate, some 
metabolites originating from the dehydroxylation of UA 
forming UB and further phase II conjugation were iden-
tified. In particular, both UB–glucuronide and UB-sul-
phate were detected in some D3-UA samples (Table  2). 
Similarly to what was reported for UB, UA-sulphate was 
the predominant urolithin metabolite in the circula-
tion for D3-UA rats. A high inter-individual variability 
was observed in the plasma concentrations of urolithins 
for both D3-UB and D3-UA animals (Table  2). Control 
plasma samples from the CTRL and D3 groups did not 
contain detectable amounts of any urolithins. The urinary 
excretion of urolithin derivatives was very limited and 
only UB-sulphate was detected in D3-UB rats (Table 2).
The analysis of tissue samples from the four experi-
mental groups revealed the presence of urolithins in 
heart, pancreas, and liver of both D3-UB and D3-UA 
rats (Fig.  1), while these metabolites were absent in 
control samples. Aglycone and sulphate forms of uro-
lithins, but not glucuronides, were detected in these tis-
sues, although they were not detected in all the samples 
(Fig. 1), in line with the inter-individual variability high-
lighted for plasma and urine. Bioaccumulation of uro-
lithin metabolites in the heart of D3-UB rats occurred in 
the form of UB and UB-sulphate (Fig. 1), without statis-
tically significant differences between the concentrations 
of these two compounds. When D3 rats were treated 
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with UA (D3-UA), UA, UA-sulphate and UB were found 
in the heart tissue. Again, no statistically significant dif-
ferences were shown among metabolites for D3-UA heart 
samples. Urolithin A and B were also present in rat pan-
creatic and hepatic tissue, as both aglycone and sulphate. 
UB and UB-sulphate were detected in D3-UB pancreas 
and liver samples, while up to four metabolites (UA, UA-
sulphate, UB, and UB-sulphate) were detected in D3-UA 
pancreas and livers. No statistical differences among 
metabolite concentrations for each treated group (D3-UB 
or D3-UA) and tissue (pancreas or liver) were observed, 
accounting for the absence of a prevailing compound. In 
general, UB, or its sulphated form, were found in tissues 
at higher concentrations with respect to UA or its sul-
phated form (Fig. 1).
Blood glucose levels and body weight
All animals had normal blood glucose levels (105 ± 1 mg/
dl), at the beginning of the experimental protocol. Two 
days after STZ injection, glycaemia significantly rose in 
diabetic rats compared with CTRL (410 ±  22  mg/dl vs 
104 ±  1  mg/dl; p  <  0.01). During the subsequent week, 
blood glucose levels increased slightly in untreated as 
well as urolithin-treated diabetic animals (~approxi-
mately 15%) and then remained stable until the end of the 
experimental protocol (after 3 weeks of hyperglycaemia: 
D3: 429 ± 18 mg/dl; D3-UA: 543 ± 22; D3-UB: 494 ± 28). 
A 7% decrease in body weight was observed during the 
first 2 weeks after STZ injection, in both untreated and 
treated diabetic animals. Subsequently, body mass exhib-
ited only negligible changes in all experimental groups.
Hemodynamics
The heart rate measured under anaesthesia was similar 
in the four groups (193 ± 7 beats per minute, 205 ± 11, 
204  ±  7, 209  ±  9 in CTRL, D3, D3-UA, and D3-UB, 
respectively). Compared with CTRL animals, D3 ani-
mals exhibited a global deterioration of hemodynamic 
performance, as indicated by the significant decrease 
in left ventricular systolic pressure (LVSP; Fig.  2a), 
the maximal rate of LV pressure rise (+dP/dtmax) and 
decline (−dP/dtmax) (Fig. 2c, d), and the marked prolon-
gation of isovolumic contraction time (IVCT; Fig.  2e) 
and total cycle duration (Tcycle; Fig. 2f ). The treatment 
with UB induced a significant recovery of most param-
eters, during both contraction and relaxation. Specifi-
cally, the values of LVSP, ±  dP/dtmax, IVCT and Tcycle 
approached those measured in CTRL animals (Fig.  2a, 
c–f ). A lower effect was observed for UA, limited to the 
contraction phase (+dP/dtmax and IVCT; Fig. 2c, e). No 
significant differences among groups were found for 
LVEDP (Fig. 2b).
Cell mechanics and calcium transients
The average diastolic sarcomere length was comparable 
in all groups (1.732 ± 0.002 µm), as well as the fraction of 
shortening (Fig.  3c). Conversely, in accordance with the 
hemodynamic data recorded in vivo, contraction/relaxa-
tion properties and intracellular calcium dynamics were 
worsened in unloaded ventricular myocytes isolated from 
D3 hearts in comparison with CTRL (Fig. 3d–f). Specifi-
cally, D3 cardiomyocytes exhibited a significant decrease 
in the maximal rate of shortening (−dL/dtmax; Fig.  3d) 
and re-lengthening (+dL/dtmax; Fig.  3e), and a prolon-
gation of re-lengthening times (TBL10%, TBL50%, and 
TBL90%; Fig.  3f ). The impaired contractility in D3 cells 
was accompanied by a significant increase in calcium 
transient amplitude (+33%, Fig. 3g) and a prolonged tau 
(+37%, Fig. 3h).
Both urolithins led to an almost complete recovery of 
cellular mechanical properties and calcium dynamics, 
with only a slightly higher effect of UB (Fig. 3d–h).
Table 2 Concentrations (μM) of the urolithins detected in plasma and urine samples of rats treated with UB and UA
n.d. not detected (below LOD), n.s not significant
a Number of samples where each metabolite was quantified/detected
b §§§ indicates p < 0.001 significant differences between D3_UA and D3_UB (Mann–Whitney U test)
Metabolite D3‑UA D3‑UB p  valueb
Median (IQR) Min–max Samplesa Median (IQR) Min–max Samples
Plasma
 Urolithin B-sulphate 0.000 (0.003) 0.000–0.012 1/6 0.339 (3.895) 0.065–5.858 9/9 §§§
 Urolithin B-glucuronide 0.019 (0.033) 0.000–0.048 5/6 0.000 (0.032) 0.000–0.064 4/9 n.s.
 Urolithin A 0.005 (0.007) 0.000–0.015 5/6 n.d. –
 Urolithin A-sulphate 0.220 (0.124) 0.121–0.394 6/6 n.d. –
Urine
 Urolithin B-sulphate n.d. 0.344 (5.622) 0.063–9.248 5/5 –
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Electrophoretic and immunoblot assay
SERCA2, PLB, and PLB-P expression. Sarcoplasmic 
reticulum (SR) calcium reuptake rate is mainly regulated 
by the SERCA2 activity which, in turn, is modulated by 
a small molecular weight protein, the phospholamban 
(PLB). The phosphorylation status of PLB (PLB-P) is 
able to remove the inhibitory effect of PLB on SERCA2, 
resulting in increased SR-Ca2+ uptake and enhanced 
myocyte contractility and relaxation [17]. On the other 
hand, alterations in SERCA2 expression and/or activity 
are recognized among the major factors contributing to 
the ventricular dysfunction observed in diabetic cardio-
myopathy [18–21].
A slight decrease (−19%; not significant) was observed 
in the expression level of SERCA2 associated with only 
negligible changes in PLB level, in D3 group as compared 
with CTRL (Fig. 4a, b), leading to a significant reduction 
in the SERCA2/PLB ratio (−35% vs CTRL, Fig.  4c). On 
the other hand, a reduced SERCA2/PLB ratio was shown 
to be associated with a parallel lessening of SERCA2 
Fig. 1 Accumulation of urolithin metabolites in tissues of rats treated with UA or UB (n = 5 for each group). Control samples (CTRL and D3 groups) 
did not contain detectable levels of these metabolites. The fraction under each column accounts for the number of samples where the compound 
was detected. For Urolithin A and Urolithin B, the y axes on the right refer to the concentration of the two metabolites in the heart tissue. §p < 0.05 
significant differences between D3-UA and D3-UB (Mann–Whitney U test). °Outlier values
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affinity for  Ca2+, resulting in altered cardiomyocyte 
mechanics and depressed left ventricular function [22, 
23]. Furthermore, diabetic hearts showed a pronounced 
decrease in PLB-P/PLB ratio (−21% vs CTRL, Fig.  4d) 
that, in the absence of substantial changes in the total 
PLB expression (Fig.  4b), suggested a reduction in the 
phosphorylated form of the protein. All these changes 
can account for the altered cellular contractile proper-
ties observed in diabetic cardiomyocytes. Although the 
effect of UB was slightly higher, both urolithins induced 
a marked amelioration of the two ratios whose values 
approached those measured in control hearts (Fig. 4c, d).
Fractalkine expression. Fractalkine, beside its action 
as a chemoattractant, is known to possess a detrimental 
effect on cardiac cells independently of inflammatory cell 
recruitment [24, 25]. The expression level of fractalkine 
(CX3CL1) was increased by hyperglycaemia (+48%; 
Fig.  4e) and significantly decreased by both urolithins 
(−33% for UA and −28% for UB; Fig. 4e).
Discussion
Cardiomyopathy is a frequent and severe complication 
of both type-1 and type-2 diabetes [26], even in the pres-
ence of good glycaemic control. Cell oxidative stress and 
moderate inflammation constitute two closely related key 
factors in the pathogenesis of diabetic cardiomyopathy 
and play an important role in the initial stages of diabetes, 
leading to an altered tissue microenvironment associated 
with cell loss and/or dysfunction. This, in turn, triggers 
the progression of the disease towards the cardiomyopa-
thy phenotype [1, 2, 27–29]. Thus, major attention should 
be focused on reducing the effects of the early key factors 
underlying the initial cellular biochemical and functional 
changes occurring in the diabetic heart.
In the last decade, different dietary relevant (poly)phe-
nols have been tested as adjuvant therapeutic tools to 
counteract initial changes in the diabetic heart, possibly 
due to their antioxidant and anti-inflammatory properties 
[2, 8, 30, 31]. In this context, we recently showed that uro-
lithins are able to reduce the pro-inflammatory response 
to high glucose levels in cultured neonatal cardiomyocytes 
and fibroblasts [13], suggesting that they can prevent the 
diabetes-induced microenvironmental changes trigger-
ing myocardial inflammation and functional impairment 
in the diabetic heart. These findings confirmed previous 
in  vitro studies demonstrating the positive role of uro-
lithin supplementation in different cell models, includ-
ing anti-inflammatory activity in endothelial cells and 
macrophages [15, 32–36] and beneficial effects on lipid 
metabolism in adipocytes and hepatocytes [37]. However, 
the biological effects of in  vivo urolithin administration 
in the setting of diabetes, as well as in other pathological 
conditions, remain to be characterized [38].
The present study demonstrates that in  vivo urolithin 
treatment, besides reducing the inflammatory state of 
cardiac tissue, can prevent the occurrence of the early 
signs of cardiac dysfunction, as measured at organ and 
cellular-molecular levels, in a rat model of diabetes, after 
3 weeks of hyperglycaemia.
Fig. 2 Hemodynamic measurements. Mean values ± SEM of left 
ventricular systolic pressure (LVSP; a), left ventricular end diastolic 
pressure (LVEDP; b), maximal rate of ventricular pressure rise (+dP/
dtmax; c), and decline (−dP/dtmax; d), isovolumic contraction time 
(IVCT; e), and total cycle duration (Tcycle; f), measured in control 
rats (CTRL, n = 10), untreated diabetic rats (D3, n = 9), and urolithin 
A-treated (D3-UA, n = 10) or urolithin B-treated (D3-UB, n = 10) 
diabetic animals. *p < 0.05 significant differences vs CTRL; # p < 0.05 
significant differences vs D3 (two-way ANOVA)
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In accordance with previous studies, showing that 
3-weeks of diabetes corresponds to a transitional 
phase preceding overt DCM phenotype [2, 21, 39], we 
observed a deterioration of hemodynamic function and 
cardiomyocyte contractile properties, associated with 
altered intracellular calcium dynamics. In the absence 
of substantial variations in SERCA2 expression levels, 
abnormalities in calcium handling and contractility could 
be attributed to a decreased SERCA2 activity, mainly 
due to a reduced phosphorylation of PLB, as we actually 
observed. A depressed cell contractility, associated with 
an increased calcium transient and a prolonged tau, is 
Fig. 3 Cell mechanics and calcium transients. Representative examples of sarcomere shortening (a) and corresponding calcium transients (b; nor-
malized traces: fold increase) recorded from CTRL, D3, D3-UA and D3-UB ventricular myocytes. In c–h bar graphs means values ± SEM of sarcomere 
fraction of shortening (FS; c), maximal rate of shortening (−dL/dtmax; d), maximal rate of re-lengthening (+dL/dtmax; e), time to 10, 50 and 90% of 
total cycle length (TBL10%, TBL50%, and TBL90%; f), calcium transient amplitude expressed as peak fluorescence normalized to baseline fluores-
cence (f/f0; g), and time constant of the intracellular calcium decay (tau; h), measured in CTRL (66 and 33 cells, for mechanics and calcium transients 
respectively), D3 (91 and 57 cells), D3-UA (100 and 63 cells), and D3-UB (102 and 42 cells). *p < 0.05 significant differences vs CTRL; # p < 0.05 signifi-
cant differences vs D3; § p < 0.05 significant differences vs D3-UA (2-factor Nested ANOVA)
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consistently observed in this model of early diabetes [2]. 
A combination of several factors should likely be consid-
ered to interpret this behavior, including abnormalities in 
mitochondrial function, low pacing rate of cardiomyo-
cytes, and SERCA2 activity. Mitochondrial dysfunction 
induced by cell oxidative stress was shown to reduce, in 
addition to ATP generation, the rate of calcium uptake 
into heart mitochondria [1]. The low pacing rate of cardi-
omyocytes (0.5 Hz) allows the removal of excess cytosolic 
calcium within the sarcoplasmic reticulum by SERCA2, 
independently of its reduced activity, and may explain the 
increased amplitude of the calcium transient following 
excitation. Nevertheless, the increase in calcium release 
does not result in an improvement in cell contractility 
due to the reduced ATP availability and the depressed 
myofilament calcium sensitivity, a hallmark of myofila-
ment dysfunction in diabetic cardiomyopathy [40].
The functional impairment was coupled with initial tis-
sue inflammation, as indicated by the significant increase 
in the expression levels of the pro-inflammatory cytokine 
fractalkine. This cytokine is expressed in early diabetes 
by cardiac fibroblasts and, to a lesser extent, by cardio-
myocytes [2]. Fractalkine can act as either a soluble or 
membrane-bound mediator and signals through the G 
protein–coupled chemokine receptor CX3CR1, which 
is expressed on different cells, including cardiomyocytes 
[25, 41]. Accumulating evidence suggests that fractalkine, 
in addition to its role in chemotaxis, can directly affect 
the intracellular contractile machinery, leading to an 
altered cardiomyocyte mechanics [25]. Fractalkine has 
been shown to induce up-regulation of different phos-
phatases, including protein phosphatase 1 (PP1) and pro-
tein phosphatase 2A (PP2A), in failing myocardium [42]. 
These phosphatases are involved in dephosphorylation of 
proteins regulating the  Ca2+ homeostasis in the myocar-
dium, and thus essential regulators of myocardial func-
tion [43]. PP1 and PP2A dephosphorylate PLB, which 
is an intrinsic protein of the sarcoplasmic reticulum 
(SR) and a key regulator of SR-Ca2+-ATPase (SERCA2). 
SERCA2 activity is enhanced when PLB is phosphoryl-
ated, resulting in increased calcium re-uptake into the SR 
and enhanced contractility [17]. The fractalkine-induced 
reduction of the phosphorylated form of PLB, via up-reg-
ulation of phosphatases, can result in depressed SERCA2 
activity and cardiomyocyte contractile dysfunction. 
We actually found a reduced PLB-P/PLB ratio associ-
ated with a significant impairment of intracellular  Ca2+ 
dynamics and cardiomyocyte mechanics.
It is necessary to consider that fractalkine may also 
affect cardiomyocyte contractility by decreasing the 
phosphorylation of cardiac troponin I, as observed in 
control ventricular myocytes under isoproterenol stimu-
lation [25]. PKA-induced phosphorylation of troponin I 
decreases myofilament calcium sensitivity, enhances slid-
ing velocity, and contributes to the acceleration of relaxa-
tion [44]. Thus, a reduced phosphorylation of troponin 
I, by altering actin-myosin interactions, may have detri-
mental effects on cardiomyocyte mechanics.
The chronic administration of both urolithin A and 
B resulted in an almost complete recovery of cellular 
mechanical properties and intracellular calcium dynam-
ics associated with a significant reduction in the tissue 
Fig. 4 Expression levels of functional proteins and fractalkine by 
immunoblot assay. Average values ± SEM of SERCA2 (a), PLB (b), 
SERCA2/PLB ratio (c), PLB-P/PLB ratio (d), and fractalkine (e, CX3CL1) 
expression levels in left ventricular myocardium of CTRL (n = 2), D3 
(n = 3), D3-UA (n = 4), and D3-UB (n = 4), in technical triplicate. Data 
are expressed in densitometric units. Sets of bands related to protein 
expression in 4 animals representative of the average behaviour 
observed in each group are reported in f. In columns 1–4 CTRL, D3, 
DR-UA, and D3-UB animals. *p < 0.05 significant differences vs CTRL; 
# p < 0.05 significant differences vs D3 (non-parametric statistical test 
Kruskal–Wallis and U Mann–Whitney test)
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level of fractalkine. The beneficial effects of the two treat-
ments could be ascribed primarily to the previously 
described action of urolithins in counteracting cellular 
oxidative stress and pro-inflammatory cytokine expres-
sion [13], which are intimately linked and constitute early 
detrimental changes in myocardial tissue of the diabetic 
heart, playing a pivotal role in DCM development.
The sulphate and glucuronide metabolites of UA and 
UB are the main metabolites appearing in circulation 
after consumption of ET-rich foodstuffs [45]. Direct i.p. 
administration of individual metabolites was the treat-
ment of choice, as it allowed bypassing the microbial ella-
gitannin transformation step, that could have caused a 
substantial rise in inter-individual variability in urolithin 
production, allowing at the same time the discrimina-
tion of the putative effects exerted by UA and UB. The 
administration of aglyconic UA and UB did not limit 
the physiological relevance of these experiments since 
the aglycones were effectively transformed into phase 
II conjugates following i.p. injection. Sulphate conjuga-
tion favoured over glucuronidation in this model and 
UA-glucuronide, which has been previously described 
as the major urolithin metabolite in circulation after ET 
consumption [45–48], was not detected. This profile in 
phase II conjugates might be related to the by-pass of the 
intestinal barrier as absorption site, key in the glucuroni-
dation of UA, and/or to the inhibition of UDP-glucuronyl 
transferases, considering the ability of UA to modulate 
phase II detoxifying enzymes [49]. On the other hand, 
the lack of substantial amounts of urolithin metabolites 
in rat urine was expected since the animals were starved 
prior to sacrifice, with urolithin metabolites having pos-
sibly already reached substantial clearance. The presence 
of metabolites in plasma several hours after treatment 
accounted for a high rate of enterohepatic recircula-
tion of urolithins, a pharmacokinetic characteristic of 
these compounds [50]. Enterohepatic recirculation of i.p. 
administered urolithins is also supported by the dehy-
droxylation of UA forming UB, mediated by unknown 
urolithin-degrading bacteria in the intestinal lumen 
[51]. However, dehydroxylation of UA by a mammalian 
enzyme cannot be ruled out [52].
Urolithin metabolites accumulated substantially in 
rat tissues, including heart ventricles. The high capac-
ity of the heart to accrue urolithins has recently been 
described [52], although to date no phase II metabolites 
have been reported. The high levels of UB metabolites in 
rat tissues is in line with a previous report highlighting 
the rapid accumulation of UB in rodent tissues compared 
to UA [52]. Interestingly, the higher concentration of UB 
and UB-sulphate in heart tissue in comparison with UA 
and UA-sulphate may explain the slightly higher effi-
cacy of UB in preventing diabetes-induced myocardial 
dysfunction both at organ and cell levels in this work. 
Another point of note is that urolithins have been identi-
fied for the first time in pancreatic tissue. This observa-
tion opens new research scenarios in the framework of 
the study of the protective effects of urolithins in diabe-
tes at the multiple organ level, especially considering the 
positive actions of some urolithins on insulin secretion 
[53].
Inter-individual variability in the production of urolith-
ins is a well-known issue [12]. Although we hypothesised 
that inter-individual variability would have been drasti-
cally reduced by using i.p. administration, a high varia-
tion in metabolite concentrations was observed. Such 
variability can be attributed, at least in part, to animal-to-
animal differences in metabolite clearance before sample 
collections. However, despite this variability in metabo-
lite concentrations, the variability in measurements of 
cardiac function at organ and cellular-molecular levels 
was extremely low. This might account for a sustained 
and chronic effect of urolithins at the cardiac level, inde-
pendent of their acute presence in circulation or even at 
heart tissue level.
Limitations
Although we achieved the primary goal of our study, 
showing that in vivo urolithin administration succeeds in 
preventing early signs of cardiac dysfunction in diabetic 
rats, we acknowledge some limitations of this study. First, 
we used a rat model of type-1 diabetes. Nevertheless, it 
should be taken into account that cell oxidative stress and 
moderate myocardial inflammation constitute early det-
rimental changes which occur in both type-1 and type-2 
diabetic hearts at the initial stages of the disease, playing 
a pivotal role in triggering the development of functional 
impairment. Secondly, we mainly attributed the cardiac 
functional recovery observed in urolithin treated diabetic 
rats to a reduced level of tissue inflammation, as sug-
gested by the significant reduction of fractalkine levels 
in myocardial tissue of D3-UA and D3-UB hearts, but 
other potential mechanisms have not been explored and 
cannot be absolutely ruled out. Finally, the intracellular 
molecular mechanisms proposed to explain the effects 
of the pro-inflammatory cytokine fractalkine on cardio-
myocyte mechanics and calcium dynamics are basically 
speculative and built on previously reported data.
Conclusions
In conclusion, we showed here for the first time that 
in  vivo urolithin administration may be able to prevent 
the initial inflammatory response of myocardial tissue to 
hyperglycaemia and the negative impact of the altered 
diabetic milieu on cardiac performance, as measured at 
cellular and organ levels. In line with previous data, our 
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findings further support the idea that dietary (poly)phe-
nols can constitute appropriate nutraceuticals and effec-
tive supplementary treatments for diabetes management 
and prevention of its complications.
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